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During the past decade a number of
pesticides, industrial by-products, manufac-
tured products such as plastics, and natural
chemicals have been shown to disrupt the
endocrine system. These chemicals are
referred to as endocrine-disrupting chemicals
(EDCs). These chemicals have received con-
siderable attention, in part because endocrine
disruption is a relatively unstudied area in tox-
icology and is only recently being taken into
account in risk assessment. The focus here is
on EDCs with estrogenic activity (EEDCs),
which are chemicals that act as hormone
mimics via estrogen receptor mechanisms; this
is currently the largest group of known
endocrine disruptors. The main purpose of
this article is to present an overview of the
mechanisms of hormone action that provide
the basis for understanding how EEDCs have
the potential to be biologically active at low,
environmentally relevant doses. Our strategy
is to discuss the receptor mechanisms mediat-
ing responses to a natural hormone, 17β-estra-
diol (E2), and then to use this information as
the basis for describing the low-dose effects of
chemicals that disrupt the normal functioning
of this hormonal system, either by mimicking,
modulating, or antagonizing the activity of
the hormone. We have chosen to use estrogen
as our example because there is more known
about the biology of estrogens and xenoestro-
gens than other components of the endocrine
system for which there is evidence for disrup-
tion by environmental chemicals; however,
the information presented here is applicable to
endocrine disruptors that interfere with other
hormonal systems.
We will begin by briefly reviewing
information concerning the relationship
between dose, receptor occupancy, and
responses (such as cell proliferation) after
binding of E2 to estrogen receptors (ER-α) in
cultured human MCF-7 breast cancer cells. A
number of speciﬁc factors inﬂuence the dose
of an EEDC that reaches the target cells to
produce a response. These factors include
route of administration, absorption, distribu-
tion, metabolism, rate of clearance, plasma
transport, cell uptake, affinity for estrogen
receptor subtype in the cell, and the interac-
tion of the ligand–receptor complex with
tissue-specific factors comprising the tran-
scriptional apparatus. This mechanistic infor-
mation provides the basis for establishing the
dose at the target site in cells (nuclear recep-
tors associated with DNA or more recently
identified receptors associated with the cell
membrane) for an EEDC required to elicit a
biological response similar to that produced
by a dose of E2 with equal estrogenic activity.
Modeling that takes into account each of
these factors would encompass physiologically
based pharmacokinetic information (1), as
well as quantitative structure-activity relation-
ships (QSAR) (2,3). We have previously dis-
cussed the factors that inﬂuence access of E2
and EEDCs from blood to estrogen receptors
in cells elsewhere (4–6). Our primary focus in
this review is on the latter part of the overall
process that occurs once an estrogenic chemi-
cal has reached the nuclear estrogen receptor.
Dose ranges. We have separated dose-
specific effects into three general categories:
the physiological dose range for estrogenic
activity, the toxicological dose range for acute
toxicity, and the environmentally relevant
dose range related to current exposures. The
physiological dose range (of estrogenic activ-
ity, whatever the source) is defined by the
normal concentration range of an endoge-
nous hormone. More speciﬁcally, with regard
to steroid hormones, the physiological con-
centration refers to the amount of free
(unbound to plasma proteins and unconju-
gated) endogenous hormone that the EEDC
is mimicking or antagonizing. The free hor-
mone concentration is generally considered to
be the biologically active portion of total hor-
mone concentration in blood (7,8) and most
accurately predicts biological activity (for
example, free triiodothyronine and free thy-
roxine, as opposed to total hormone concen-
tration, are routinely used for clinical
diagnosis). The toxicological dose range is
identified by some measure of toxicity, such
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Information concerning the fundamental mechanisms of action of both natural and
environmental hormones, combined with information concerning endogenous hormone concen-
trations, reveals how endocrine-disrupting chemicals with estrogenic activity (EEDCs) can be
active at concentrations far below those currently being tested in toxicological studies. Using only
very high doses in toxicological studies of EEDCs thus can dramatically underestimate bioactivity.
Speciﬁcally: a) The hormonal action mechanisms and the physiology of delivery of EEDCs predict
with accuracy the low-dose ranges of biological activity, which have been missed by traditional
toxicological testing. b) Toxicology assumes that it is valid to extrapolate linearly from high doses
over a very wide dose range to predict responses at doses within the physiological range of receptor
occupancy for an EEDC; however, because receptor-mediated responses saturate, this assumption
is invalid. c) Furthermore, receptor-mediated responses can ﬁrst increase and then decrease as dose
increases, contradicting the assumption that dose–response relationships are monotonic. 
d) Exogenous estrogens modulate a system that is physiologically active and thus is already above
threshold, contradicting the traditional toxicological assumption of thresholds for endocrine
responses to EEDCs. These four fundamental issues are problematic for risk assessment methods
used by regulatory agencies, because they challenge the traditional use of extrapolation from high-
dose testing to predict responses at the much lower environmentally relevant doses. These doses
are within the range of current exposures to numerous chemicals in wildlife and humans. These
problems are exacerbated by the fact that the type of positive and negative controls appropriate to
the study of endocrine responses are not part of traditional toxicological testing and are frequently
omitted, or when present, have been misinterpreted. Key words: dose response, endocrine disrup-
tors, estrogen action, estrogen receptors, fetal development, inverted U, MCF-7 cells. Environ
Health Perspect 111:994–1006 (2003). doi:10.1289/ehp.5494 available via http://dx.doi.org/
[Online 2 February 2003]
Research Reviewas death in the extreme case, a decrease in
body weight, or malformations in a develop-
mental study. The environmentally relevant
dose range can be established for chemicals
where there is information concerning levels
monitored in air, food, or water or, less com-
monly, if there is information based on moni-
toring of biological tissues in wildlife or
human populations.
It is important to note that during fetal
and early postnatal life, the pharmacokinetics
of chemicals and drugs are markedly different
relative to adulthood, and pregnant and non-
pregnant females also differ in this regard.
Therefore, dose ranges in pregnant females
and fetuses cannot be assumed to be the
same as in adults and should be evaluated
separately.
Low-dose range. The physiological and
the environmentally relevant dose ranges typi-
cally fall well below the toxicological dose
range based on using established protocols for
examining acute toxic effects of chemicals.
Exceptions would be instances of industrial
accidents or workplace exposure, such as the
Yu-Cheng incident in Taiwan involving acci-
dental exposure to acutely toxic doses of poly-
chlorinated biphenyls (PCBs) (9) or exposure
to synthetic estrogens by workers in pharma-
ceutical plants (10).
At a meeting hosted by the National
Institutes of Health (NIH) at the request of
the U.S. Environmental Protection Agency
(U.S. EPA), devoted to the low-dose issue
(11), low dose was deﬁned as doses below the
range typically used in toxicological studies,
where the dose range seldom extends more
than 50-fold below the maximum tolerated
dose (MTD) in an animal (12,13). The phys-
iological and the environmentally relevant
ranges we describe here fall within this low-
dose range deﬁned at the NIH meeting. For
example, the MTD for the plastic monomer
bisphenol A is 1,000 mg/kg/day (14). The
U.S. EPA calculated a reference dose (RfD)
based on a LOEL (lowest-observed-effect
level) of 50 mg/kg/day; this was because a no-
observed-adverse-effect level had not been
determined, and adverse responses occurred at
the lowest dose tested. The RfD of bisphenol
A based on application of a safety factor of
1,000 was calculated to be 50 µg/kg/day (15).
The environmentally relevant amount of
bisphenol A, however, has recently been deter-
mined on the basis of direct measurement in
the blood of human fetuses at term. Parent
(unconjugated, aglycone) bisphenol A concen-
trations ranged from 0.2 to 9.2 ng/mL, with a
mean ± SD of 2.9 ± 2.5 ng/mL (16).
Developmental exposures. Although the
issues discussed in this review apply to expo-
sure to endocrine disruptors at any time in
life, it is generally accepted that EDCs have
the greatest impact when exposure occurs
during development (17,18). In describing
the in vivo effects of EDCs, we will emphasize
effects of endocrine disruptors on fetal devel-
opment. During fetal life, endogenous hor-
mones regulate the differentiation and growth
of cells, and developmental processes appear
to have evolved to be exquisitely sensitive to
changes in hormone concentrations. A conse-
quence of this evolved strategy of develop-
ment being epigenetic (that is, based on
signals that cells are exposed to rather than
due to a ﬁxed genetic program) is that even in
animals that are genetically identical, small
ﬂuctuations in endogenous hormonal signals
during development provide the basis for sig-
nificant variability in phenotype (19). This
provides the mechanism via which even slight
alterations in hormonal activity due to expo-
sure to EDCs during very brief critical devel-
opmental periods in fetal life can potentially
lead to irreversible changes in the course of
differentiation of cells. These cellular changes
are associated with permanent alterations in
gene activity and organ function (20,21).
Implications. We will review mechanistic
information showing that failure to apply fun-
damental principles of hormone receptor biol-
ogy to dose selection in toxicological studies
can potentially lead to a huge error in estimat-
ing risk associated with exposure to doses
below the NOEL (no-observed-effect level)
determined in traditional toxicological studies.
These issues are problematic for toxicology,
because they challenge the traditional use of
extrapolation from high-dose testing to predict
responses at much lower environmentally rele-
vant doses. Additionally, these data also pro-
vide evidence that some traditional
assumptions used in risk assessment for sys-
temic (noncarcinogenic) toxicants, such as the
assumption of a threshold (22) and a monoto-
nic dose–response relationship (23), cannot be
uniformly applied to EDCs (24,25). We will
relate our ﬁndings regarding effects of very low
doses (within the range of human exposure) of
bisphenol A (the monomer used to manufac-
ture resins and polycarbonate plastic and used
as an additive in many other products) and
methoxychlor (a currently used insecticide) to
current methods of risk assessment for sys-
temic toxicants. The classiﬁcation of EDCs as
systemic toxicants is due to an absence of data
and is not based on ﬁndings of no genotoxic
effects, particularly for estrogenic EDCs (26).
Because estrogen is implicated in a number of
cancers, both as an initiator and promoter,
environmental chemicals that mimic estrogen
cannot be ruled out as carcinogens. In particu-
lar, research is needed to determine whether
exposure to EDCs during early life is related
to the development of cancer later in life
(26,27). A recent example of a relevant ﬁnding
is that at very low doses (0.1–10 nM,
0.023–2.3 ng/mL), bisphenol A induces pro-
liferation of human prostate cancer cells via
binding to a mutant form of the androgen
receptor found in some prostate tumors (28).
It has been known for decades that some
environmental chemicals mimic the activity
of endogenous hormones. However, the
mechanistic information we provide here con-
cerning the functioning of the hormonal sys-
tems being disrupted by these chemicals was,
in general, not considered in designing toxi-
cological studies conducted to assess safety.
This is especially true with regard to doses
administered, long-term consequences of
exposure during sensitive periods in develop-
ment, and types of end points examined.
With regard to dose, if the mechanistic infor-
mation concerning hormone action that we
review here had been considered, the cur-
rently accepted practice of only testing very
high doses to predict effects of doses thou-
sands or even millions of times lower would
have been recognized as inappropriate. The
result would have been that doses of EDCs
such as methoxychlor and bisphenol A far
below those currently being described as safe
would, in fact, have been predicted to pro-
duce biological responses, and much lower
doses would have been tested. A recent dose
range–finding study of the dietary estrogen
genistein (29) has used a wide range of multi-
ple doses including a low-dose range, and
these studies illustrate the importance of this
approach (29,30). On the basis of the infor-
mation provided here, we propose that toxi-
cological testing procedures incorporate a
much wider dose range, take into account the
heightened sensitivity and unique effects
(some of which may not be apparent until
adulthood) that can occur as a result of
endocrine disruption in the fetus, and shift to
measuring functional changes in organs
(focusing on continuous variables), rather
than low-frequency dichotomous variables
such as malformations associated with acute
toxicity.
Mechanisms of Estrogen
Action Predict Low-Dose
Effects of EEDCs
Although the mechanism of action of most
toxicants is unknown, the mechanism of
action for estrogens, including EEDCs, is
already known in substantial detail; however,
much remains to be learned. For an EEDC to
exert a direct estrogenic effect in a cell, the
cell must have estrogen receptors (whether the
receptors are located in the nucleus, cyto-
plasm, or cell membrane). With regard to
nuclear receptors, the most critical piece of
information regarding the mechanism of
action of an EEDC is deﬁned by its binding
affinity for the subtype of estrogen receptor
(alpha or beta) present in the cell. Once
afﬁnity for the receptor is estimated, one can
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literature concerning the interaction of estro-
genic chemicals with receptors to understand
a considerable amount about the mechanisms
of action of the chemical. Understanding the
mechanism of action for a toxicant allows the
incorporation of this information into pre-
dicting appropriate doses to use in toxicologi-
cal studies (11). In this section we will
describe the relationship between dose, recep-
tor occupancy, and responses, such as cell
proliferation, after binding of E2 to estrogen
receptors (specifically, ER-α) in cultured
human MCF-7 breast cancer cells. In a subse-
quent article (31), we will relate this informa-
tion to the results of in vivo experiments
showing that the bioactive concentration of
E2 in serum during development in mice and
rats is very similar to the bioactive concentra-
tion that stimulates cell proliferation in
human MCF-7 cells. This information will
provide the basis for determining doses of
EEDCs that produce effects similar to those
caused by an increase in E2 during develop-
ment in mice, as well as effects caused by low
doses of EEDCs administered at other times
in life.
Lipophilic and hydrophilic hormones.
Hormones do not act directly, but rather indi-
rectly, through binding to specific receptor
proteins. When these receptor proteins are
occupied by hormone, they become the signal
transduction system for inducing the hor-
monal response. Two basic transduction sys-
tems for hormones have been identified.
Hydrophilic hormones, such as the hypothala-
mic and pituitary hormones, do not easily
cross cell membranes, but instead bind to the
extracellular domain of transmembrane recep-
tors; binding of the hydrophilic hormone to
the membrane-bound receptor results in acti-
vation of complex intracellular signaling path-
ways that can lead to rapid changes (in
seconds) in cell function (32). The second
transduction system is used by lipophilic hor-
mones, including the sex steroids such as E2,
which are small (molecular weight of a few
hundred daltons) lipophilic molecules that can
diffuse into cells. These hormones bind to
intracellular receptors and induce transcription
of specific genes (a much slower process).
These intracellular receptors act as ligand-
dependent transcription factors and belong to
the nuclear receptor superfamily that, in
addition to estrogen receptors, includes recep-
tors for triiodothyronine, retinoic acid, vita-
min D3, cortisol, androgens, progesterone,
and aldosterone (33–35). In addition to acting
via binding to nuclear receptors, there is now
considerable evidence that estradiol interacts
with transmembrane receptors to stimulate
rapid responses in some cells (36–39).
Although hydrophilic and lipophilic
hormones act through different receptor
systems, both require receptor occupancy as a
precursor to produce a response in target cells.
There is a critical aspect of this issue with
regard to the potential for species differences
in the response to EEDCs. It is well known
that the gene structure and ligand-binding
properties of the classical estrogen receptor
(ER-α) have been highly conserved (that is,
have experienced relatively little change)
among vertebrates separated for up to 300
million years of evolution. Thus, the binding
of an estrogenic chemical to ER-α in fish,
amphibians, reptiles, birds, and mammals
(including humans) shows relatively little dif-
ference (40–42). Binding to the receptor is the
initiating step in endocrine disruption by
estrogenic chemicals. It is during events prior
to and subsequent to receptor binding that
species and tissue differences emerge in terms
of differences in absorption and metabolism,
as well as speciﬁc genes regulated by estrogen.
There are also tissue-specific components of
the transcriptional apparatus (receptor coregu-
lators) involved in determining which genes
are regulated by ligand-activated receptors
(43,44).
Even within a specific tissue in a single
organism, there are developmental changes
in the genes regulated by specific hormones
(45). In addition, with regard to unique
developmental effects of EEDCs, there is
evidence that the functioning of enzyme
systems involved in metabolizing endoge-
nous steroids, drugs, and EDCs differs dur-
ing fetal life and in adulthood (46,47).
Regardless of these species, tissue, and life
stage differences, if a chemical can bind to
estrogen receptors in fish, the evidence is
that it will also bind to estrogen receptors in
humans and other vertebrates. Until there
are data to the contrary, one would expect
that the possibility of endocrine disruption
occurring in humans can be predicted by
assessing binding of an estrogenic chemical
to estrogen receptors in any vertebrate.
With regard to estrogenic EDCs and their
potential for disrupting embryonic develop-
ment, the similarity between vertebrates
with regard to the mechanism of action of
estrogenic chemicals that act via binding to
estrogen receptors argues strongly for the
continued use of animal models to assess
human risk (40–42). Within the field of
comparative endocrinology, the finding of
highly conserved molecules such as estradiol
and the estrogen-receptor complex has led
to the general assumption that it is the spe-
cific uses to which hormones and their
receptors have been put that has changed
throughout the evolution of multicellular
organisms, not the hormones and receptors
themselves (48).
Relationship between hormone concentra-
tion and receptor occupancy. There are four
properties of receptors that predict responses
to estrogen and other hormones. The first
property is afﬁnity of the ligand for the recep-
tor, which must be high enough for a suffi-
cient number of receptors to be occupied at
the concentrations at which the natural or
manmade estrogen is present. The second
property is saturability. As binding of the hor-
mone to its receptor shows the property of
saturation, there is no further increase in
number of occupied receptors as a function of
increase in dose once all receptors are occu-
pied. Likewise, biological responses to hor-
mones saturate; interestingly, saturation of
response frequently occurs considerably below
100% receptor occupancy in what has been
traditionally termed “spare receptor” observa-
tions (we cover this in more detail below).
The third property is ligand speciﬁcity, as all
compounds that show hormonal activity (or
receptor-mediated antihormonal activity)
must bind to the hormone receptor, whereas
compounds that at a given concentration do
not have hormonal activity (or antihormonal
activity) do not bind to the receptor. The
fourth property is tissue speciﬁcity of receptor
distribution. Tissues that respond to the pres-
ence of a hormone must have receptors for
the hormone. If a given cell does not have
receptors for the hormone, that hormone is
“invisible” to that cell, and the cell can show
no primary response to the hormone,
although indirect (secondary) effects may be
observed. At concentrations above those
within a normal physiological range, hor-
mones may bind to receptors for other hor-
mones. For example, E2 binds to androgen
receptors at concentrations approximately
100 times higher than the concentrations
required to occupy estrogen receptors and
induce responses (49). The biological conse-
quences of “cross-talk” with other receptors at
high doses of a ligand have not been well
characterized for most systems, but this likely
contributes to qualitatively different effects at
low (physiological) and high (toxicological)
doses. We discuss dose–response issues in
more detail below.
Receptor occupancy is directly linked to
responses, and responses to either a natural
estrogen or an EEDC are brought about in
relation to the number of occupied recep-
tors. Above 10% receptor occupancy, and
particularly above 50% receptor occupancy,
which mathematically deﬁnes the Kd (the dis-
sociation constant from the law of mass action
applied to receptor–ligand binding kinetics) of
the binding of hormone and receptor, receptor
occupancy is never determined to be linear in
relation to hormone concentration. Using a
less stringent definition of linearity, propor-
tionality between receptor occupancy and hor-
mone concentration is observed below 10%
receptor occupancy, and the relationship
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(such as cell proliferation) is also only propor-
tional below 10% receptor occupancy. We
will thus consider that the relationship
between receptor occupancy and hormone
concentration, as well as between receptor
occupancy and response, are approximately
linear up to 10% receptor occupancy. At con-
centrations above the Kd, saturation of
response occurs ﬁrst, and then at higher con-
centrations, saturation of receptors is observed.
An example based on administration of E2
to MCF-7 cells of the relationship between hor-
mone concentration, receptor occupancy, and a
response (cell proliferation) is presented in
Table 1. The data in Table 1 show that as hor-
mone concentration increases by factors of 10,
receptor occupancy typically increases by the
following relationship: a) If the hormone con-
centration is 1% of its Kd (% Kd: Table 1, mid-
dle column), the number of receptors occupied
is also approximately 1% of total receptors.
b) With a 10-fold increase in hormone concen-
tration to 10% of the Kd, receptor occupancy
increases to approximately 9%. c) The next 10-
fold increase in hormone concentration is to
the Kd and leads to 50% receptor occupancy.
d) With another 10-fold increase in hormone
concentration, 91% of receptors are occupied.
e) Finally, another 10-fold increase in hormone
concentration only leads to a small increase,
from 91 to 99% receptor occupancy.
The importance of the data in Table 1 is
that while at the lowest concentration refer-
enced, a 10-fold increase in hormone leads to
a 9-fold increase in receptor occupancy (from
1 to 9%), between the highest doses, a 10-fold
increase in hormone concentration only leads
to less than a 1.1-fold increase in receptor
occupancy (from 91 to 99%). The practical
result is that while at hormone concentrations
below 10% receptor occupancy (10-fold
below the Kd) receptor occupancy is close to
proportional to hormone concentration, this is
not the case above this concentration. The
view of the previously mentioned “spare
receptor” hypothesis from this perspective is
that a system such as this, which we assume
evolved to be responsive to small changes in
ligand concentration, could only operate in a
portion of the binding range that was nearly
linear (below 10% receptor occupancy), thus
leading to the observation that there appeared
to be receptors that were in surplus over those
needed for responses, hence spare receptors.
Surplus hormone receptors over the number
of occupied receptors required for response
(50,51) was recognized early in the study of
the steroid receptors and steroid receptor-
mediated action (52).
At the dose ranges of EEDCs used in
current toxicity testing, chemicals are likely to
be present within target cells at concentra-
tions many orders of magnitude above their
Kd for estrogen receptors. Within this dose
range, changes in hormone concentration
cannot have a detectable effect on receptor
occupancy, because all receptors are saturated
at 100% and no additional binding, which is
required to result in an increase in response,
can be observed. No primary hormonal
effects can be observed in response to changes
within this high-dose range, but only sec-
ondary effects not mediated by estrogen
receptors.
Relationship between receptor occupancy
and response. It is sometimes erroneously
assumed that hormones act in vivo at their Kd
(50% receptor occupancy). With a few excep-
tions, the physiological ranges for natural hor-
mones (more specifically, the free, bioactive
fraction (7,8) of the total circulating) are typi-
cally below the Kd. A biological basis for this
observation may be that if natural hormone
concentrations were at or above the Kd and
thus near receptor saturation, even quite large
changes in hormone concentrations would
result in only a small change in occupied
receptors. This type of system would be rela-
tively insensitive to changes in hormone con-
centrations and would require dramatic
changes in hormone concentrations to elicit
changes in response. Because very small
changes in hormone concentrations, for exam-
ple, a 50% increase, were associated with
changes in responses in animal studies, it
appears that the working range for hormones
must be well below the Kd, and indeed the
animal data support this hypothesis
(19,23,53,54).
In many biological systems, saturation of
response is observed well below saturation of
receptors, and saturation of speciﬁc responses
may even occur below the Kd. As indicated
above, the spare receptor hypothesis is the
term applied to this kind of observation
(55–58) and has been described in detail, par-
ticularly on the basis of observations with
transmembrane receptors. Speciﬁcally, trans-
membrane receptors show a much greater
percent inhibition as the dose of ligand
increases (~ 90%) than do nuclear receptors
that are members of the nuclear receptor
superfamily (~ 50%) (59,60). The potential
contribution to nonmonotonic dose–response
curves of the loss of receptors as dose of
ligand increases is covered below.
There is only near-linearity of dose and
occupancy up to a dose that results in 10% of
receptors being occupied (below 0.01 nM for
E2), and the near-linear range between dose
and response is even more restricted (shifted
to the left). For example, although the Kd for
E2 binding to ER-α is approximately 0.1 nM,
a significant increase in proliferation of
MCF-7 estrogen-responsive breast cancer cells
is seen with addition of 0.0004 nM E2 to
estrogen-free medium. Half-maximal prolifer-
ation is seen at 0.001 nM E2, and near-
maximum proliferation is seen between 0.01
and 0.1 nM. Thus, almost 91% of maximal
cell proliferation is observed at a concentra-
tion 10-fold below the Kd, at a ligand concen-
tration approximately 100-fold lower than
91% of receptor saturation (Table 1). The
relationship between hormone response and
receptor occupancy is not limited to perma-
nent cell lines and has also been described for
a number of estrogenic chemicals in primary
rat uterine cells, where, as above, saturation of
response occurs before saturation of receptor
occupancy (61).
Interestingly, for E2, the dose required to
induce different responses in the same cell is
not the same. For example, in GH3 rat pitu-
itary cells in vitro, proliferation of cells is half
maximal at an E2 concentration between
0.001 and 0.01 nM, whereas synthesis of
prolactin is half-maximally induced at
0.1 nM (62). Progesterone receptors in
MCF-7 cells require roughly 10 times more
E2 for induction relative to proliferation (63),
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Table 1. Mathematical calculations of receptor occupancy versus hormone concentration for an example
where the Kd = 0.1 nM.a
Cell proliferation,
Estradiol concentration Receptors (% of maximum
(nM) (ng/mL)b Percent of Kd occupied (%)c response)d
10 2.72 10,000 99 100
1 0.272 1,000 91 100
Kd 0.1 0.0272 100 50 99
0.01 0.00272 10 9 91
PRe 0.001 0.000272 1 1 50
0.0001 0.0000272 0.1 0.1 9
aThis Kd was chosen because it represents a midrange value commonly measured for the binding of estradiol to the
estrogen receptor. bng/mL = ng/g = µg/kg = ppb. cThe mathematical relationship described here between ligand concen-
tration and receptor occupancy applies to receptor–ligand interactions for all hormones, although each ligand will have a
unique Kd associated with 50% receptor occupancy. dThis column in the table represents a physiological response, in this
example, the estrogen-dependent proliferation of MCF-7 human breast cancer cells. eThe physiological range (PR),
occurring at an EC50 of 1 pM for cell proliferation, was determined from both in vitro stimulation of cell proliferation at 1
pM = 0.27 pg/mL (Figure 1) and free E2 at EC50 = 0.2 pg/mL (54), and in vivo studies where free E2 = 0.21 to 0.54 pg/mL (23,53)
and is within the range of 1% receptor occupancy. Note that here, as in many systems, response saturates (e.g., 99%
response at 0.1 nM and 50% receptor occupancy) well before receptor occupancy saturates (e.g., 10 nM and 99% recep-
tor occupancy).similar to induction of prolactin in GH3
cells. This relationship demonstrates that the
activation of different genes requires different
numbers of receptors to be occupied.
Importantly, both of these responses saturate
at a percent receptor occupancy far below
receptor saturation, that is, spare receptor
kinetics still apply.
Nonmonotonic Dose Response
to Estrogens
Nonmonotonic (inverted-U) dose–response
relationships: in vitro effects of low and high
doses of estrogens. Responses to hormones,
including estrogens, saturate as does receptor
occupancy, and therefore cannot be linear as a
function of an increase in dose within the
high-dose range. Further, for many responses
to a wide range of concentrations, across
many powers of 10-fold, the dose–response
relationship is nonmonotonic as well, with
response decreasing at doses above those that
initially reach a level of saturation. There are a
number of published examples of this in vivo
and in vitro. In male mouse fetuses, a very
small increase in E2 or a physiologically
equivalent increase in estrogenic activity by an
estrogenic chemical such as diethylstilbestrol
(DES) resulted in prostate enlargement
detected later in life (23,64–66). In marked
contrast to these findings, consistent with
numerous prior studies, administration of
much higher doses of either natural or man-
made estrogens during the prenatal or neona-
tal period of prostate development caused a
reduction in prostate size relative to untreated
males (23,64,66–69).
The lower doses of DES that resulted in
an increase in prostate size (23,64,65) were
predicted to increase total serum estrogenic
activity within a physiological range, based on
studies of the free concentration of DES in
serum (5) and transplacental transport of
radiolabeled DES in pregnant mice (47).
Specifically, a low dose of DES of 0.02
µg/kg/day administered to pregnant mice was
predicted to lead to an increase in free,
bioavailable DES in the fetus that falls within
the physiological dose range of free, bioavail-
able estrogenic activity during normal fetal
development (54); this exposure led to the
prostate enlargement response (23). This dose
of DES, in the physiological range of estro-
genic activity, falls within the low-dose range
of exposure. In contrast, in the same studies, a
10,000-times higher dose of DES (200
µg/kg/day) resulted in gross abnormalities in
the reproductive organs, including a marked
reduction in prostate size (23,64). This dose
of DES therefore falls within the toxicological
dose range and represents a high-dose range
of exposure.
There are many additional examples of
nonmonotonic dose–response relationships.
For example, it has been known for some
time that there are adverse effects at low and
high doses, on either side of an optimum
physiological range for normal development,
for other ligands that bind to receptors in the
steroid receptor superfamily, such as vitamin
A and thyroid hormone. It is difﬁcult to com-
pile a literature focusing on inverted-U
dose–response curves, as these types of
dose–response functions are common in
endocrine studies and are often not identiﬁed
in titles or abstracts as a noteworthy ﬁnding.
Among those that have been reported, non-
monotonic dose–response curves can occur at
several levels of organization, ranging from
the biochemical based on in vitro studies
(28,54,62,70–75) to the organ or system level
based on in vivo studies (23,60,66,76–82).
MCF-7 cell in vitro model for inverted-U
endocrine dose responses. MCF-7 human
breast cancer cells (83) are a permanent cell
line that contains estrogen receptors. These
cells have retained estrogen responsiveness for
a sustained period of continuous cell culture
and show estrogen-dependent stimulation of
cell proliferation by natural and xenobiotic
estrogens (84–86). In addition, the same
chemicals that stimulate growth at lower
concentrations can slow MCF-7 cell growth
at higher concentrations (72,73, for example)
and inhibit growth by acute cytotoxicity at
high concentrations in the micromolar (ppm)
range (Figure 1A). The dose–response range
required to observe these dual effects by nat-
ural and xenobiotic estrogens can be very
wide, spanning 1,000- to 100,000-fold for
bisphenol A and octylphenol up to and
exceeding 100 million-fold for DES and E2
(Figure 1A) (54). These cell responses in tis-
sue culture to very wide concentration ranges
create a type of inverted-U dose response that
can be used as an in vitro model.
Low-dose stimulation of cell proliferation
followed by high-dose cytotoxicity is illus-
trated in Figure 1A in estrogen-responsive
MCF-7 cells. Growth was stimulated by E2 in
the concentration range from 0.1 pM to 100
pM. This low part-per-trillion (ppt) range is
the physiological range for E2 determined in
studies of free estradiol in rats and mice from
fetal life through adulthood (23,53); this is
the low-dose range indicated in the figure.
The cell growth response was saturated and
did not increase with increased hormone con-
centration from 100 pM through to 1 µM.
Above 1 µM (the high-dose range indicated
in Figure 1A), however, cytotoxicity reduced
the cell growth response to E2, with inhibi-
tion of response to below the control level at
100 µM. The physiological dose range for E2
action was approximately 100 million times
lower (0.1–1.0 pg/mL culture medium;
0.1–1.0 ppt; the low-dose range) than the
toxicological dose range that results in acute
toxicity (which occurred at 10–100 µg/mL
culture medium, or 10–100 parts per million
(ppm); the high-dose range).
The acute cytotoxicity of E2 in cultured
MCF-7 cells did not depend on the presence
of estrogen receptors. We have derived clonal
cell lines from MCF-7, including cell line
C4-12-5, which no longer express estrogen
receptors and are completely estrogen nonre-
sponsive and proliferate in the absence or
presence of estrogen (87); re-expression of
estrogen receptors in these clonal cell lines
can lead to recovery of estrogen-dependent
cell proliferation (88). As stated above, with-
out receptors, these C4-12-5 cells are “blind”
to the presence of the hormone. Cytotoxicity
occurred within the same high-dose range of
E2 in the clonal C4-12-5 cells (derived from
MCF-7 cells) that do not express estrogen
receptors (Figure 1B) as in the parental
MCF-7 cell (Figure 1A); however, the low-
dose range effects to stimulate cell prolifera-
tion could not be demonstrated in the
estrogen-nonresponsive cells (Figure 1B).
These estrogen receptor–negative variants
proliferate in the absence of estrogen, and in
the absence of estrogen receptors, low doses
of estrogen are the incapable of eliciting
effects in these cells.
Importantly, stimulatory effects of
estradiol in the low-dose range could also be
obliterated in estrogen-responsive MCF-7 cells
by the presence of a background or contami-
nating level of another estrogen such as DES
(Figure 1C). Background estrogenic activity
due to contamination by addition of DES at
only 3 ppt (10 pM DES) completely obscured
the low-dose range effects of E2 on cell prolif-
eration, but did not impair detection of the
high-dose range, toxic effects observed above 1
µM E2 (above 0.3 ppm; Figure 1C). Although
this background contamination was created
experimentally with 3 ppt DES, the presence
of contaminating estrogens in the phenol red
pH indicator dye included in most tissue cul-
ture media limited the recognition of and
acceptance of estrogen-dependent cell prolifer-
ation by MCF-7 cells until 1985 (63,89,90).
Unrecognized estrogenic contamination may
interfere with any study, in vitro or in vivo,
unless this possibility is excluded by the per-
formance of appropriate controls.
Overall, both low-dose and high-dose
effects by E2 were observed in MCF-7 cells
(Figure 1A). Demonstration in vitro of the
low-dose effects of E2, but not the high-dose
effects, was obscured by testing in the absence
of estrogen receptors (Figure 1B) or by testing
in the presence of a low level of a contaminat-
ing estrogen (Figure 1C). The objective of
appropriate control procedures discussed
below is to allow one to distinguish whether
negative results are due to an actual lack of
activity of a compound, or rather due to
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tion that is obscuring all responses.
Importance of Valid Positive
and Negative Controls for
Endocrine Responses
Although E2 was clearly capable of exerting
effects in the physiological, low-dose range
(Figure 1A), demonstration of the low-dose
effects was system dependent. Importantly,
the inability to detect the low-dose effects of
E2 in Figure 1B and C was due to the experi-
mental conditions and was not due to the
absence of estrogenic activity by E2 itself or
due to an absence of the potential to show
estrogen responses in uncontaminated
MCF-7 cells with estrogen receptors. This
conclusion will only be realized if specific
positive and negative controls are included to
allow for the correct interpretation of results.
Without evaluation of the appropriate nega-
tive and positive controls, it is not valid to
conclude that a chemical lacks low-dose
estrogenic activity simply because it fails in
assays that may be represented by the condi-
tions in Figure 1B, where the test system is
unresponsive, or in Figure 1C, where the test
system is responsive but contaminated. In
these examples, if the controls were omitted
(or ignored), E2 itself in its own physiological
concentration range (as well as any other
estrogenic chemical) would be wrongly iden-
tified as inactive in two out of three assay
systems.
The positive and negative controls. Each
panel of Figure 2 illustrates specific positive
and negative controls relevant to each experi-
ment in Figure 1; this includes use of an
antiestrogen (AE), which is a competitive
antagonist of estrogen action (90,91). These
controls allow one to interpret the absence of
detectable low-dose effects in Figure 1B and
C, either as the lack of cellular responsiveness
to estrogen generally, or as the presence of a
masking estrogenic contamination.
A concentration of E2 that saturates the
proliferative response in the low-dose range is
used as a positive control. This treatment
demonstrates the presence of estrogen respon-
siveness in the assay relative to the negative
control that is estrogen free (Figure 2A). An
antiestrogen such as raloxifene or ICI
182,780 is used to confirm a baseline for
estrogen receptor activation in the negative
control treatments; there should be no reduc-
tion in response by the antiestrogen because
no receptor-mediated responses have been ini-
tiated in the absence of estrogen (Figure 2A).
If an inhibition of response is observed in the
presence of antiestrogen with no intentional
addition of estrogen (Figure 2C), then the
conclusion is that estrogenic stimulation is
occurring in the system from contamination.
Another important issue is that when high
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Figure 1. MCF-7 human breast cancer cell proliferation at low through high doses. (A) Stimulation of
MCF-7 cell proliferation in estrogen-free medium by E2 up to a dose at which E2 is cytotoxic. Control line
indicates estrogen-free medium. (B) Lack of response to E2 by estrogen receptor–negative, estrogen-non-
responsive C4-12-5 cells derived from MCF-7 cells, in estrogen-free medium. Proliferation is independent
of dose up to a dose that is cytotoxic. Control line indicates estrogen-free medium. (C) Lack of response to
E2 by estrogen-responsive MCF-7 cells to E2 due to the presence of a background of 10 pM DES (3 ppt)
added to the estrogen-free medium to mimic contamination and present in all dose groups. Proliferation is
independent of dose up to a dose that is cytotoxic. “Control” line indicates estrogen-free medium plus the
3 ppt DES background. High-dose effects of E2 are seen in A, B, and C, whereas low-dose effects are visi-
ble only in A, the dose response performed in estrogen-responsive MCF-7 cells examined in the absence
of detectable background estrogen. In A the concentration range is shown simultaneously as molarity (M),
as mass per milliliter, and as mass ratio (ppq: parts per quadrillion). Half-maximal stimulation of prolifera-
tive response occurred at approximately 1 pM E2 in medium (0.272 ppt) in the low-dose range, whereas
inhibition was induced at micromolar concentrations in the high-dose range. Estrogen-dependent cell pro-
liferation and cytotoxicity were determined exactly as described in prior publications (72,138,139). Brieﬂy,
the very wide dose responses (54) were performed for E2 by incubating the indicated cells in 24-well
plates for 4 days in culture medium (phenol red-free medium, charcoal-stripped serum) plus E2 at concen-
trations from 0.01 or 0.1 pM through 100 µM, with daily medium changes. Proliferation was determined by
DNA assay at the end of the incubation, and results were expressed as percent of the control; control
100% values were 1.0, 3.7, and 5.5 µg DNA/well for A, B, and C, respectively. Values are the mean and
standard error of measurements in replicate wells; n = 3.
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MCF-7 estrogen-responsive, against a background of 10 pM DES (3 ppt)doses of a chemical are being examined for
estrogenic activity, after demonstrating that
addition of antiestrogen inhibits the response,
competitive reversal of this inhibition of
response by co-incubation with an excess of
estrogen (for example, 10 nM E2) (Figure 2C)
added with the antiestrogen is in turn used to
distinguish antiestrogenic activity from toxic-
ity due to the combined action of the test
chemical and antiestrogen. This last step is
the final element in discriminating between
antiestrogenic activity of a compound and
acute toxicity (91).
Interpretation of the controls. In Figure
2A, the positive control E2 at 100 pM stimu-
lated response, and of equal importance,
exposure to an antiestrogen at 100 nM (AE)
in the absence of any E2 did not reduce the
proliferative response below the control level
of growth. The interpretation drawn from
the controls in Figure 2A is that a) the MCF-
7 cell system was estrogen responsive, and
importantly, b) under the negative control
growth conditions, there was no detectable
background estrogenic contamination. In
this system, both low- and high-dose effects
of E2 were observed (Figure 1A).
Figure 2B shows the same controls
applied to C4-12-5 cells, a clonal variant of
MCF-7 cells that lacks estrogen receptors.
Positive control E2 did not stimulate cell pro-
liferation, and furthermore, the antiestrogen
did not inhibit proliferation of the C4-12-5
cells (Figure 2B). The interpretation of these
controls is that the C4-12-5 cells are estrogen
nonresponsive, showing responses neither to
low-dose estrogen nor to antiestrogen.
Importantly, even though the cells were not
responsive in the low-dose range of exposure,
the proliferation of the estrogen receptor–
negative C4-12-5 cells was still inhibited by
E2 in the same high-dose range that inhibited
proliferation of the estrogen-responsive
MCF-7 cells (Figure 1B); only high-dose
toxic effects of E2 were observed, and these
are clearly not mediated by nuclear estrogen
receptors.
Finally, as can be seen in Figure 2C, even
in the same MCF-7 cells that were responsive
within the low-dose range in the full dose
response (Figure 1A), a very slight back-
ground level (contamination) of an estrogenic
chemical was sufﬁcient to eliminate detection
of the low-dose stimulating effect of estradiol,
if treatments are compared only with a nega-
tive control that is presumed, without testing,
to be estrogen-free. In Figure 2C, it can be
seen that the positive control E2 added to the
“Control” medium did not stimulate further
growth, and without further information, the
system would be incorrectly interpreted as
nonresponsive in the low-dose range (Figure
1C). Incubating cells in the “Control”
medium plus antiestrogen, however, inhibited
cell proliferation, indicating the potential for
an estrogen receptor–driven stimulation of
cell growth. Competitive reversal of the antie-
strogen effect with a surplus of E2, indicated
by the light blue bar in Figure 2C, conﬁrmed
that the inhibition was antiestrogenic and not
due to nonspeciﬁc toxicity.
The interpretation of the dose–response
experiment (Figure 1C) is now that the
MCF-7 cells were fully responsive to E2 in the
low-dose range but were already maximally
stimulated by background estrogenic contam-
ination in the presumed negative control.
DES at only 3 ppt was sufﬁcient to fully mask
the low-dose effects of E2; only high-dose,
toxic effects of E2 could be observed
(Figure 1C). In the absence of the appropriate
controls, or if the controls were misinter-
preted or ignored, E2 itself, an unquestioned
estrogen, would be incorrectly identiﬁed from
Figure 1B or C as an inactive chemical in the
low-dose range (its physiological range), but
not in the high-dose range, with respect to
estrogen-dependent cell proliferation.
Implications. Positive and negative
controls such as those described above are
needed for adequate interpretation of EEDCs
in the context of low-dose effects, nonlinear
saturation of response, and reversal of
response that can generate a nonmonotonic
dose–response relationship. Of great impor-
tance, research on low-dose effects requires a
new level of understanding of ambient estro-
genic activities, and controls are absolutely
required to assess these activities experimen-
tally. Ambient estrogenic activities for in vitro
studies consist of contaminants in air, media,
or plastic, whereas in vivo, ambient estrogenic
activities could include variable background
levels of endogenous hormone as well as activ-
ity from a variety of external sources such as
feeds. Appropriate controls are not typically
included in toxicological tests conducted for
regulatory purposes.
Relevant to this discussion are findings
that the concentration of E2 in cell culture
medium that results in proliferation at
approximately 50% of maximum is very close
to the concentrations of free serum E2 during
development in mouse and rat fetuses
(0.2–0.3 pg/mL) (23,53). Even slight varia-
tions in the levels of estradiol have been
related to differences in the course of develop-
ment in mice, rats, and gerbils (19,23,92–94).
For example, we experimentally increased the
free serum estradiol concentration in male
mouse fetuses from the control level of
0.2–0.3 pg/mL (via a Silastic capsule contain-
ing estradiol implanted in the pregnant dam).
This 0.1 pg/mL increase in free serum estra-
diol resulted in a marked change in develop-
ment of the urogenital system in the male
fetuses (23).
Taken together, these ﬁndings indicate a
very high degree of sensitivity (well below a
part per trillion) of both human and rodent
tissues to E2 both in vitro and in vivo. This
high degree of sensitivity to very small pertur-
bations in E2 provides the basis for concern
about the use of appropriate controls to test
for background contamination by estrogenic
chemicals in studies with animals. Estrogenic
contamination can occur via the food
(95,96), caging (97), or bedding (98), as well
as in studies with cultured tissue via compo-
nents of media (63), or plastic tubes and
cultureware (99,100). Although there have
been studies that have examined the effects of
components of diets on steroid synthesis in
humans (101), this issue has not been a focus
of toxicological studies involving EEDCs.
Our recent ﬁndings show that in mice main-
tained on different types of commercial ani-
mal feeds during pregnancy, serum estradiol
levels in fetuses are markedly different
(unpublished observation).
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Figure 2. The relevant controls for the dose responses of Figure 1A–C. (A) Estrogen-responsive MCF-7
cells in estrogen-free medium. (B) Estrogen receptor–negative, estrogen-nonresponsive C4-12-5 cells
derived from MCF-7 cells, in estrogen-free medium. (C) Controls. Estrogen-responsive MCF-7 cells in the
presence of a background of 10 pM DES (3 ppt) added to the estrogen-free medium and present in all
media and treatments including controls. Abbreviations: AE, 100 nM antiestrogen (raloxifene or ICI
182,780); AE + E2 10–8 M, 100 nM antiestrogen (raloxifene or ICI 182,780) plus E2 at 10–8 M; C, control estro-
gen-free medium; “C”, estrogen-free medium plus 3 ppt DES; E2, 100 pM E2. Values are the mean and stan-
dard error of measurements in replicate wells; n = 3.Endocrine Mechanisms
Mediating Errors in Estimating
Low-Dose Responses from
High-Dose Studies
The default risk assessment assumes linearity
of dose response. Major errors in assessing risk
can be made when linearity of response and
the preceding receptor occupancy is assumed
across the entire dose range, which is the cur-
rent assumption used in risk assessment.
Although almost everyone involved in risk
assessment recognizes that the assumption of
linearity is invalid (even for cancer) (102), the
application of safety factors that results in lin-
ear extrapolation across a wide dose range
remains the default for current risk assess-
ment. For example, safety factors (used to cal-
culate a “safe” dose for human exposure) of
10-fold each are often used to estimate each
of the following: human risk from animal
studies, to account for variability within the
human population, when the lowest dose
tested results in an adverse response (termed
the LOEL), and most recently, as an added
safety factor for protecting children.
Application of these 10-fold safety factors
results in linear extrapolation from a LOEL or
NOEL (determined by testing a few very high
doses) to arrive at a safe dose. Thus, in
practice, the model upon which risk assess-
ment is practiced assumes that this linear
extrapolation procedure is valid and will result
in calculation of a dose that is safe for humans
exposure.
Error of a linear estimate relative to
actual receptor occupancy. When a linear
extrapolation model is applied to a saturating,
receptor-mediated response to estimate the
risk of an adverse response, this linear esti-
mate results in a false assumption concerning
the actual reduction in response (and thus
risk) that occurs with decreasing dose. The
error we refer to is illustrated in the simpliﬁed
graphic example in Figure 3. The use of 10-
fold safety factors to estimate occupancy of
receptors (and subsequent responses) on the
basis of results from animal studies assumes a
linear relationship between dose and response,
even though this may not be overtly acknowl-
edged. We will initially discuss the theory
behind the error that occurs on the basis of
extrapolation from very high to very low
doses assuming a linear function and then
provide examples from actual data for DES,
genistein, and bisphenol A obtained from in
vitro studies using MCF-7 cells. The error we
refer to here based on receptor occupancy is
in reality lower than the error based on actual
responses, as responses can saturate at lower
concentrations than those required to achieve
receptor saturation (Table 1). Therefore, our
calculations of error in Table 2 are, in fact,
conservative.
For simplicity here, in the discussion
below we will not discriminate between dose
administered and dose at the estrogen recep-
tor in target cells and will simply refer here to
a test dose. The reason for this is that for in
vitro studies conducted in serum-free
medium, the administered dose and the dose
available to bind to estrogen receptors are very
similar (4). In vivo this is obviously not the
case due to absorption, metabolism, clear-
ance, plasma binding, etc., all of which are far
more complicated to study in developing
fetuses than in adults (54). It is nonetheless
the basis of modern endocrinology that a dose
at target does exist, whether or not it can be
easily determined, and that this dose deter-
mines the response and its magnitude relative
to the receptor occupancy it can generate.
Our discussion here is meant to apply to the
dose at target.
It is important to note that during fetal
and early postnatal life, the pharmacokinetics
of chemicals and drugs are markedly different
relative to adulthood. In addition, pregnant
and nonpregnant females also differ in this
regard. Data from studies with adult animals
thus cannot be used to predict the pharmaco-
kinetics of chemicals in pregnant females and
fetuses (16,103,104). Thus, evidence that a
particular chemical is cleared rapidly in a
nonpregnant adult cannot be used to dis-
count the possibility of achieving a much
higher dose at target in fetuses and neonates
(46). Unfortunately, for most chemicals,
there are no pharmacokinetic data and thus
no basis for predicting dose at target for the
most susceptible subpopulation: pregnant
females and their fetuses.
The test dose for purposes of our
discussion here is a high dose administered in
toxicological experiments that is used to pre-
dict responses at much lower doses. As shown
in Table 1 and Figure 3, the relationship
between hormone concentration and receptor
occupancy is approximately linear at low
receptor occupancy (Figure 3, test dose exam-
ple at 1/4 Kd). As the test dose exceeds the
range of approximate linearity, for example, a
test dose at 80% receptor occupancy (Figure
3 at 4 × Kd), the linear model (linear extrapo-
lation from test dose to zero dose) will clearly
underestimate actual receptor occupancy and
will thus underestimate the actual responses
that would occur at lower doses (Figure 3,
arrow labeled “error of the linear estimate”).
This deviation from linearity has great impor-
tance with regard to the strategy of using very
high doses of EEDCs in toxicological studies
and extrapolating to predict responses at
much lower doses.
Table 2 presents specific quantitative
information for a number of chemicals. With
regard to understanding the error that can
occur in estimating the potential for low-dose
responses on the basis of extrapolating from
high to low doses across a wide dose range, we
will describe an in vitro experiment in which
bisphenol A was examined in MCF-7 cells as
an example. For our example here, the test
dose for bisphenol A (shown in Table 2,
row 1) is 844,000 ppb (844 mg/kg), chosen
for its relation to Kd for ER-α and for prox-
imity to test doses administered in prior in
vivo toxicological studies of bisphenol A
(again, using this as the dose at target) (14).
Under the assumption that the test dose of
844,000 ppb is within a linear response range
and therefore within a linear receptor occu-
pancy range for direct hormonal effects,
reducing the dose by 50% (to a dose of
422,000 ppb) would lead to the prediction
that receptor occupancy would also drop by
50% (Table 2, row 2). In fact, because the
test concentration is so much higher than the
Kd, virtually no actual change in receptor
occupancy occurs (the actual change in recep-
tor binding in MCF-7 cells would be from
99.99 to 99.98% with this 50% reduction in
dose), and no change in response mediated by
these receptors would be detected.
When one administers a dose of
bisphenol A that is 10-fold lower than the test
dose (84,400 ppb or 84.4 mg/kg), receptor
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Figure 3. Error in predicting actual receptor occu-
pancy based on linear estimation applied to a satu-
rating test dose. Receptor occupancy (solid line) is
graphed against a linear scale of ligand concentra-
tion from 0 to 0.5 nM, where the Kd for ligand
binding = 0.1 nM. Linear estimations to zero
concentration (dotted lines) are shown originating
from single measurements at two test doses, one
below the Kd (square point of origin, at 1/4 Kd =
0.025 nM) and one above the Kd (round point of ori-
gin, at 4 × Kd = 0.4 nM). This assumes no back-
ground-contaminating estrogenic activity from
either endogenous or exogenous sources other
than the chemical being tested. Where the test
dose used as the origin of the linear estimation is
below the Kd, the linear estimation is very close to
actual occupancy. Where the lowest test dose
used as the origin of the linear estimation to zero
dose is above the Kd, the linear estimation deviates
substantially from actual receptor occupancy, indi-
cated as “Error of the linear estimate.” The fold-
underestimate of occupancy, and therefore
underestimate of response for receptor-mediated
events, increases as the origin of measurement
increases above the Kd and is calculated in Table 2
for a number of EEDCs where the origin is 10,000-
fold above the Kd, which could not be shown to
scale on this ﬁgure.occupancy still only drops from 99.98% to
99.90% in MCF-7 cells (Table 2, row 3), and
again, this change is not likely to be a
detectable decrease in binding. This decrease
in dose also would thus not be likely to lead
to a detectable decrease in response mediated
by these receptors. Even at a dose of 844 ppb,
which is a dose 1,000 times lower than the
test dose of 844,000 ppb, 90.91% of recep-
tors will still be occupied in MCF-7 cells. On
the basis of the information presented in
Table 1, one would not expect to approach
the region of maximum detectability for a
change in response until doses that resulted in
less than 50% receptor occupancy (the Kd)
were reached. In addition, on the basis of
results in Table 1, it is apparent that responses
can occur at concentrations in the range of
1% receptor occupancy. As shown in Table 2,
at the concentration of bisphenol A that
results in approximately 1% receptor occu-
pancy (0.844 ppb), or 1 million times lower
than our initial test dose, the linear extrapola-
tion model would have predicted negligible
receptor binding, and thus no response, based
on a test dose of 844,000 ppb.
Nonmonotonic dose–response curve,
response to endogenous hormone, and an
assumed threshold dose all increase the mag-
nitude of the error of a linear estimate. Our
calculations are based on receptor occupancy,
which is a physical chemical parameter sub-
ject to less between-species variation and
greater precision of measurement than is the
measurement of response. Cellular responses,
however, occur at doses associated with very
low receptor occupancy: the cell in essence
amplifies the receptor signal. Therefore, use
of receptor occupancy is in fact conservative
relative to the ultimate physiological
responses on which risk assessment would be
based. For example, if these calculations were
based on the EC50 (effective concentration
50%; 50% response) for a specific cell
response such as cell proliferation that is 10-
to 100-fold lower than the Kd (Table 1), then
the underestimate of the potential for a
response would be 10- to 100-fold higher, or
up to 1,000,000-fold, instead of the 10,000-
fold in this example.
Incorporation of additional features of
real-world risk assessment will further add to
the error, not reduce it. A nonmonotonic
dose response, speciﬁcally the inverted U, can
substantially increase the error of the linear
estimate based on a high-dose reference point
(that is well below the maximum response
because of the inverted-U dose–response
curve). This is illustrated qualitatively in
Figure 4A, where the error of the linear esti-
mate for response is compared with that for
an inverted-U dose response from a reference
point above the dose that results in the maxi-
mum response. To avoid the possibility of
this type of error, it is necessary to examine a
much wider range of doses than is typical in
toxicological studies involving animals.
Finally, as illustrated in Figure 4B, the
default risk assessment applied to EEDCs
assumes the existence of a threshold. But
when xenoestrogen activity is added to a nat-
ural system that is already responding to
endogenous estrogen such as estradiol, any
threshold in estrogenic response must already
be exceeded by the endogenous hormone.
This absence of a threshold in response to
exogenous estrogen has been experimentally
confirmed in an experiment concerning the
regulation by estrogen of sex determination in
reptiles (22). The assumption of no response
up to an assumed threshold above the zero
EEDC dose, when this is not the case, will
result in a great, potentially infinite error if
linear extrapolation is used instead of actually
determining the shape of the dose–response
curve (Figure 4B).
Figure 4B also depicts the error associated
with examining a test chemical with estrogenic
activity, such as bisphenol A, that adds to an
existing background level of endogenous
estradiol, which is variable because of endoge-
nous and exogenous factors (19). Variation in
endogenous estradiol is related to variation in
phenotype in rodents (105), supporting the
hypothesis that endogenous estrogen is already
above threshold for estrogen-mediated
responses (22). There can thus be no thresh-
old for responses to exogenous EEDCs. This
ﬁnding is important, as background levels of
endogenous estradiol markedly alter the
response of fetuses to endocrine disruptors
administered to pregnant mice and rats,
including EEDCs such as bisphenol A
(93,94). This issue is also relevant with regard
to comparing effects of EEDCs at different
life stages. During fetal life in males and
females, pregnancy, or proestrus in females,
estradiol levels are significantly higher than
during postnatal life in males or prior to
puberty and during diestrus in females (53).
These marked differences in the background
levels of estradiol will obviously influence
responses to low doses of EEDCs. The
importance of endogenous estradiol levels in
the response to low doses of EEDCs, which
has been ignored in toxicological studies and
in the models used in risk assessment, is
covered in more detail below.
Implications for current risk assessment.
For an EEDC such as bisphenol A, with a rel-
ative estrogenic activity approximately
10,000-fold less than E2 in MCF-7 cells [but
not necessarily other tissues where it is much
more active; (64)], the range of estrogenic
activity of this chemical equivalent to that of
physiological E2 would be approximately
0.05–30 ppb (0.05–30 ng/mL) within target
cells. There are now numerous published
reports that bisphenol A shows estrogenic
activity at and below this concentration in a
variety of cell culture systems (4,28,100,
106–112). For example, Gupta (64) reported
that a 50-pg/mL (50 ppt) dose of bisphenol A
signiﬁcantly stimulated prostate gland forma-
tion and growth of the fetal mouse prostate in
primary culture, similar to a 0.5-pg/mL dose
of DES. Bisphenol A stimulated human
prostate cancer cells to proliferate at a dose of
1 nM (~ 0.23 ppb) (28).
The currently accepted LOEL dose of
bisphenol A of 50 mg/kg/day (15) was
reported from high-dose toxicological studies
(14,113). This study is typical in that it used
doses 50,000–500,000-times higher than the
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Table 2. Error in estimating responses to low doses, in the physiological range of estrogenic activity, for estradiol, DES, genistein, and bisphenol A as a result of
assuming linearity across the entire dose–response curve with regard to predicted versus actual estrogen receptor occupancy.
Actual Occupied receptors ≈ Fold underestimation
Estradiol DES Genistein Bisphenol A receptors predicted by of response by
Row (ppb) (ppb) (ppb) (ppb) occupied (%) linear model (%) linear extrapolationa
1 test doseb 272 568 475,000 844,000 99.99 100 1
2 136 284 238,000 422,000 99.98 50 2
3 27.2 56.8 47,500 84,400 99.90 10 10
4 2.72 5.68 4,750 8,440 99.01 1 100
5 0.272 0.568 475 844 90.91 0.1 900
6 Kd
c 0.0272 0.0568 47.5 84.4 50 0.01 5,000
7 0.00272 0.00568 4.75 8.44 9.09 0.001 9,000
8 0.000272 0.000568 0.475 0.844 0.99 0.0001 10,000
aFold underestimation of response by linear extrapolation is the actual receptors occupied divided by the predicted receptors occupied. bThe dose in row 1 is referred to in the text as
the "test dose," at a dose 10,000-times higher than each Kd; calculated from Kd values of 0.1 nM (0.0272 ppb) for estradiol (approximate), 0.212 nM (0.0568 ppb) for DES, 176 nM (47.5 ppb)
for genistein, and 370 nM (84.4 ppb) for bisphenol A (4,5). cRow contains concentrations at the respective Kd of each compound.2- and 20-µg/kg/day doses we administered to
pregnant mice on the basis of our calculation
of an amount of bisphenol A that our prelimi-
nary findings accurately predicted would be
bioactive in male mouse fetuses (4). The
transplacental transport of bisphenol A has
now been studied in greater detail in rodents
(103,114–116), and the doses we used would
result in unconjugated bisphenol A levels in
mouse fetuses that are within the range meas-
ured in human umbilical cord blood (16,103).
Effects using low doses of bisphenol A,
which are in the new low-dose range below
the LOEL based on testing very high doses,
have now been reported in rodent studies on
mammary gland (117), vagina (118), prostate
(4,64,65,119,120), sperm production
(121,122), epididymis (64,121), rate of
embryonic development (123,124), pituitary
response to E2 (109), and rate of growth and
timing of puberty in females (93,125). There
are also reports of effects of bisphenol A in
mollusks, ﬁsh, and frogs at very low concen-
trations, including below 1 µg/L (1 ppb)
(126–132). Even though a few studies have
reported no effects of low doses of bisphenol
A, the weight of the evidence now clearly
supports that such effects occur in both
vertebrates and invertebrates.
It is also interesting that in two highly
publicized studies using low doses of
bisphenol A (133,134), no effects of
bisphenol A were found; in addition, no
effects of their positive control chemical,
DES, were found. Although DES at the dose
used was questioned as a valid positive control
by one of the groups (135), its validity as a
positive control estrogen at the low doses used
in these studies was fully endorsed by the
National Institute of Environmental Health
Sciences Low-Dose Peer Review Panel (11).
In each of the two studies, the control ani-
mals were obese (30% over normal body
weight) relative to mice used in prior studies
that used the same strain and age and that
had shown effects of fetal exposure to bisphe-
nol A and positive control chemicals (4,136),
including the same low dose of DES
(23,64,82) used by Ashby et al. and Cagen
et al. (133,134). The fact that the control ani-
mals in both the Ashby and Cagen studies
were obese and had enlarged prostates and
then did not respond to either bisphenol A or
the positive control DES suggests that the
interaction of components of the diet with
manmade chemicals, such as bisphenol A, is
an issue that requires further study; our recent
studies have confirmed this prediction
(unpublished data). This also serves as an
example of the importance of attending to
information provided by the appropriate
negative and positive controls (Figure 2),
which these authors ignored (11).
Conclusions
Information about the mechanism of action
of EEDCs, together with information con-
cerning mechanisms of hormone action, pre-
dict that current risk assessment assumptions
can lead to a dramatic underestimation of
responses (and thus risk) associated with
exposure to low doses of EEDCs, particularly
during development when the effects of very
small changes in hormonal activity are perma-
nent (54,64). The practice of examining only
a few very high doses and then extrapolating
to predict effects of doses thousands or
millions of time below those being studied is
especially problematic for endocrine
disruptors. The necessity for including low
doses in the physiologically relevant range of
estrogenic activity, as opposed to only very
high doses, when testing for effects of
endocrine disruptors is dictated by a) evi-
dence that estrogenic chemicals (as well as
other hormone mimics or chemicals that oth-
erwise interfere with endocrine function) can
produce nonmonotonic dose–response curves
where responses both increase and decrease
across the dose range, and b) the theoretical
absence of a threshold for environmental
chemicals that operate via receptors (such as
the estrogen receptor) for endogenous ligands,
such as E2; the threshold issue is covered in
more detail elsewhere (13,22). In addition,
controls valid for the positive determination
of endocrine responsiveness must be included,
and when included, interpreted appropriately,
particularly when results that are apparently
negative are obtained. The potential for error
inherent in drawing strong positive conclu-
sions from purely negative data has clearly not
been appreciated by some toxicologists
(133,134), as well as regulators responsible for
assessing this information.
Taken together, the above in vitro
ﬁndings show the substantial error that occurs
as a result of extrapolating on the basis of
findings using very high doses to predict
effects at environmentally relevant doses,
which are often thousands or millions of
times lower than doses being tested.
Responses to low doses of EEDCs should be
determined by testing a much wider range of
doses than the 50-fold range common in toxi-
cological studies today (13), including doses
in the environmentally relevant range, and by
accounting for all sources of estrogenic
activity (endogenous and exogenous) and
their interactive effect (137).
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